An accurate test to detect genetic abnormalities
LIFECELL, India’s premier mother and baby diagnostics company and stem cell bank, launched “Pentastic”an ultrasound and biochemistry-based blood test undertaken in the first trimester of pregnancy between 11 to 13 weeks to screen for genetic abnormalities, structural malformations in the foetus, and serious high blood pressure in pregnancy. Compared to conventional screening tests that use only two analytes, the new Pentastic test incorporates five analytes to predict the risk. Addition of these new analytes can significantly improve the detection of these abnormalities whilst simultaneously lowering the number of false alarms raised. This would lead to substantial improvements in health outcomes whilst providing a higher level of reassurance for expectant parents. Another significant advantage of the Pentastic test is that it helps in detecting pre-eclampsia in the first trimester. This is a medical condition that increases the risk both for mother and the baby during pregnancy. Conventional biochemical screening and even advanced DNA-based tests such as NIPT do not help in identifying this condition.